Leveraging Biomarkers and Translational Medicine for Preclinical Safety – Lessons for Advancing the Validation of Alternatives to Animal Testing

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Thomas Hartung1,2, Nicholas M. P. King3, Nicole Kleinstreuer4, Marcel Leist2,5 and Danilo A. Tagle6 1Center for Alternatives to Animal Testing (CAAT), Doerenkamp-Zbinden-Chair for Evidence-based Toxicology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; 2CAAT-Europe, University of Konstanz, Germany; 3Critical Path Institute, Tucson, AZ, USA; 4National Institute of Health, National Institute for Environmental Health Sciences, DTT/NICEATM, Durham, NC, USA; 5In vitro Toxicology and Biomedicine, University of Konstanz, Konstanz, Germany; 6National Institute of Health, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA

Please sign in or register for FREE

If you are a registered user on WORC.Community, please sign in